Figure 3

Proportional reductions in mortality and loss to follow-up necessary to maintain parity with antiretroviral therapy alone for different quarterly supplement costs, stratified by BMI. Quarterly supplement costs are represented by diagonal lines. Projected reductions in the historical quarterly mortality and loss to follow-up rates are plotted on the x-axis and y-axis, respectively. For a given quarterly supplement cost, the combination of the proportional reduction in mortality and loss to follow-up would need to fall below the diagonal line to be more cost-effective than ART treatment alone. Abbreviations: ART, antiretroviral therapy; BMI, body mass index.